Join us on Wednesday, May 8^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Wednesday, May 8, 2024
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Management of Non-Small Cell Lung Cancer (NSCLC) with an EGFR Mutation
• Therapeutic Approaches for Patients with NSCLC and Other Actionable Genomic Alterations

Target Audience
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Acknowledge available and emerging clinical trial findings with EGFR tyrosine kinase inhibitors (TKIs) for nonmetastatic non-small cell lung cancer (NSCLC) with an EGFR mutation, and identify patients for whom treatment with this novel approach would be warranted.
• Develop an optimal approach to the care of patients with newly diagnosed metastatic NSCLC with an EGFR mutation, considering the implications of recent data sets, mutation type, symptomatology, sites and extent of metastases and other factors.
• Describe mechanisms of tumor resistance to EGFR TKIs, and discern how available and investigational therapies can be optimally employed in the protocol and nonresearch care of patients with progressive NSCLC with an EGFR mutation.
• Understand the biology of EGFR exon 20 insertion mutations, and optimally incorporate currently available agents into the care of patients with these abnormalities.
• Communicate the efficacy and safety of approved ALK inhibitors to patients with localized and metastatic NSCLC for whom these therapies would be appropriate.
• Evaluate available clinical trial findings with novel MET inhibitors for patients with metastatic NSCLC with MET exon 14 skipping mutations, and identify candidates for therapy with these novel compounds.
• Consider available research information and guideline recommendations to individualize first- and later-line therapy for patients with NSCLC and a HER2 mutation or amplification.
• Recall other oncogenic pathways (eg, ROS1, RET, KRAS G12C) mediating the growth of tumors in unique subsets, and consider published and emerging data with commercially available and investigational agents exploiting these targets.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology. 

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Gainor — Advisory Committees: AI Proteins, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, ITeos Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mariana Oncology, Merck, Merus, Mirati Therapeutics Inc, Moderna, Novartis, Novocure Inc, Nuvalent, Pfizer Inc, Sanofi, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Pfizer Inc, Merck, Novartis, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, NextPoint Therapeutics, Novartis, Palleon Pharmaceuticals. Dr Reckamp — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Novocure Inc; Contracted Research: Blueprint Medicines, Calithera Biosciences, Daiichi Sankyo Inc, Elevation Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Novartis.